Abstract Methylation of promoter CpG islands has been associated with gene silencing and demonstrated to lead to chromosomal instability. Therefore, some postulate that aberrantly methylated CpG regions may be important biomarkers indicative of cancer development. In this study we used the Illumina GoldenGate Methylation BeadArray Cancer Panel I for simultaneously profiling methylation of 1,505 CpG sites in order to identify methylation differences in 76 liver tissues ranging from normal to pre-neoplastic and neoplastic states. CpG sites for ESR1, GSTM2, and MME were significantly differentially methylated when comparing the pre-neoplastic tissues from patients with concomitant hepatocellular carcinoma (HCC) to the pre-neoplastic tissues from patients without HCC. When comparing paired HCC tissues to their corresponding pre-neoplastic nontumorous tissues, eight CpG sites, including one CpG site that was hypermethylated (APC) and seven (NOTCH4, EMR3, HDAC9, DCL1, HLA-DOA, HLA-DPA1, and ERN1) that were hypomethylated in HCC, were identified. Our study demonstrates that high-throughput methylation technologies may be used to identify differentially methylated CpG sites that may prove to be important molecular events involved in carcinogenesis.
Introduction
High-throughput genomic technologies are increasingly being used in science and industry to identify therapeutic targets and risk-factors for specific diseases. As some notable examples, gene expression microarrays have been successfully used in differentiating two types of leukemia (Golub et al. 1999) , and as prognostic meta-signatures for breast cancer (van't Veer et al. , 2003 , lung adenocarcinoma (Beer et al. 2002) , and diffuse large B-cell lymphoma (Rosenwald et al. 2002) . As in other disease areas, through use of high-throughput technologies, a vast amount of information is being accumulated for the study of hepatocellular carcinoma (HCC). To date, most high-throughput genomic research in HCC has emphasized gene expression levels (Iizuka et al. 2004; Mas et al. 2006; Nam et al. 2005) . However, the importance of epigenetic events is being elucidated, as aberrant methylation has been reported to lead to chromosomal instability (Baylin et al. 2000 (Baylin et al. , 2001 . In fact, methylation has been demonstrated to lead to genetic damage in colorectal tumors (Jones and Laird 1999) . It has therefore been postulated that genomic aberrations may result from epigenetic events rather than being the causal events which lead to the development of cancer (Baylin et al. 2000 (Baylin et al. , 2001 . Moreover, aberrant methylation may directly affect gene expression by interfering with transcription factors. Unfortunately, the contribution of DNA methylation to the molecular pathogenesis of HCC is not well understood. Since methylation sensitive polymerase chain reaction (MSP) has been used in most studies examining methylation in HCC, most studies have examined a single or a limited number of genes (Jicai et al. 2006; Kondo et al. 2000; Qiu et al. 2007; Wong et al. 1999 Wong et al. , 2000a . We postulated that methylation may play an important role in the pathogenesis of HCC, and that high-throughput screening of CpG sites may readily identify methylation events important in hepatocarcinogenesis.
Two previously published studies used high-throughput technologies for studying DNA methylation in HCC patients. In an early study that used restriction landmark genomic scans, investigators examined *1,200 spots and identified the number of spots that changed between HCC and non-cancerous liver samples, concluding that the number of spots that changed was of prognostic importance (Itano et al. 2000) . However, they did not clone any of the eight spots reported to be consistently changing in the HCC samples. In a more recent study that used methylated CpG island amplification microarrays (MCAM), researchers examined 6,458 CpG islands and identified 719 hypermethylated CpG islands (Gao et al. 2008) . However, in this study only 10 HCC patients samples were examined using MCAM and significant CpG islands were determined by a fold-change threshold rather than statistical significance. As the cirrhotic liver has been described as being premalignant or a preneoplastic condition (McCaughan et al. 2002) , herein we studied a set of homogeneous samples having a common underlying etiology of cirrhosis due to HCV infection, and used the Illumina GoldenGate Methylation BeadArray Cancer Panel I for simultaneously profiling methylation of 1,505 CpG sites in 76 liver tissues representing the progression to hepatocellular carcinoma combined with inferential testing to identify methylation events important in hepatocarcinogenesis.
Materials and methods

Patients and samples
Liver tissue from 20 HCV-HCC tumors and their adjacent non-tumorous HCV-cirrhotic tissues as well as 16 independent HCV-cirrhotic tissues from patients without concomitant HCC were procured from patients undergoing liver transplantation. The Institutional Review Board approved the study protocol at Virginia Commonwealth University and written informed consent for procuring the tissue samples was obtained from all patients. In addition, 20 normal liver tissues were procured. Characteristics of the included study subjects are reported in Table 1 . Since global hypomethylation and promoter-specific hypermethylation have been implicated in the process of aging, we selected this subset of 20 normal liver tissues from among the set of available normal donor livers as having age C40 years, to closely match the age distribution of the HCV-cirrhosis and HCV-HCC patients included.
Illumina GoldenGate Methylation BeadArray DNA was isolated using QIA amp DNA Mini Kit (Qiagen) according to the manufacturer's instructions. The EZ DNA methylation kit (Zymo Research) was used for bisulfite conversion of all DNA (1 lg) samples. Universal Methylated DNA standard (Zymo Research) was included in duplicate in the plate (methylated and bisulfite treated). After bisulfite treatment, the remaining procedures were identical to the GoldenGate genotyping assay (Fan et al. 2003) , using Illumina-supplied reagents and conditions. Specifically, in this study the GoldenGate Methylation Cancer Panel I was used as the methylation assay. For each CpG site, two pairs of probes are required: an allele-specific and locus-specific oligo designed to match the methylated target sequence and an allele-specific and locusspecific oligo designed to match unmethylated target sequence. After extension and ligation, the ligated products were amplified using universal primers and hybridized to an Illumina 96-sample Universal Array Matrix (SAM) for interrogating CpG sites. The array hybridization was conducted under a temperature gradient and the arrays were imaged using a BeadArray Reader. To assess performance of the system, DNA from 12 samples (6 paired HCV-HCC and adjacent HCV-cirrhotic samples) underwent bisulfite conversion procedure independently and were hybridized. Two controls were hybridized in duplicate; the duplicate controls were aliquots from the same tube post-bisulfite conversion.
Evaluation of methylation using MethyLight reactions
For validating the Illumina results for selected genes (APC, GSTP1, PITX2, and ERBB2), a set of samples hybridized to Illumina Universal Array Matrix were also evaluated using MethyLight (Eads et al. 2000; Trinh et al. 2001) . Seventeen liver tissue samples, including two normal livers, five HCV-cirrhotic tissues, and five paired HCV HCC tumor and adjacent non-tumorous HCV-cirrhotic liver tissues studied using Illumina were included in the validation study. Methylation-specific TaqMan probes and specific primers were used in the reaction for each of the four genes. EpiTect Methylight Assays (Hs_ERBB2 and Hs_PITX2) (Qiagen, Valencia, CA) were used with EpiTect Methylight PCR kit. In addition, primers and probes were synthesized for APC and GSTP1 (Applied Biosystems). These dual-labeled probes were methylation-specific oligonucleotides with a fluorophore (FAM or VIC) and a quencher moiety attached (TAMRA). After sodium bisulfite conversion, genomic DNA was amplified (Initial activation: 5 min 95°C, 15 s 95°C, 60 s 60°C for 45 cycles) and the fluorescence was detected by the laser detector of the ABI 7700 Sequence Detection System (Perkin Elmer, Foster City,CA). A no template control, a fully methylated genomic DNA (EpiTect Control DNA methylated, Qiagen, Valencia, CA) and an unmethylated DNA (EpiTect Control DNA unmethlyated, Qiagen, Valencia, CA) were used as controls in each plate.
Statistical methods
Each CpG site is represented by a specific beadtype, and the assay incorporates *30 beads per beadtype such that the redundancy enhances the assay's reproducibility. For each array i and CpG site (or beadtype) j, beadtype expression for the red (methylated) and green (unmethylated) channels was estimated by averaging the intensities over the beads within the beadtype, yielding R ij and G ij . Background was estimated separately for the methylated and unmethylated states as the average intensity of the negative control beads for the red (Rb i ) and green channels (Gb i ), respectively, and was then subtracted from the beadtype intensities on array i. Thereafter, a summary statistic representing ''percent methylated'' was estimated as the methylated signal (M ij ) divided by the sum of the methylated (M ij ) and unmethylated (U ij ) signals after background adjustment, symbolically
where the maximum of the background corrected intensity and 0 was taken to avoid calculation of negative percent methylated values. Data processing was performed using the beadarray package (Dunning et al. 2007 ) in the R programming environment (R Core Development Team 2007). These data have been made publicly available in NCBI's Gene Expression Omnibus (Barrett et al. 2005; Edgar et al. 2002) and are accessible through GEO Series accession number GSE18081 (http://www.ncbi.nlm.nih. gov/geo/query/acc.cgi?acc=GSE18081).
For each CpG site, the paired HCV-HCC and adjacent HCV-cirrhotic tissues were compared with respect to percent methylated using a paired t-test. In addition, a Jonckheere-Terpstra test was applied to identify whether there was a significant monotonic trend in percent methylation across the independent normal, HCV-cirrhotic, and HCV-HCC tissues. In other words, for testing whether there was a significant increasing monotonic trend the null hypothesis tested was H 0 : b Normal b HCVÀcirrhosis b HCVÀHCC against the alternative that one of the inequalities was strict. Similarly, for testing whether there was a significant decreasing monotonic trend the null hypothesis tested was H 0 : b Normal ! b HCVÀcirrhosis ! b HCVÀHCC against the alternative that one of the inequalities was strict. When comparing the HCV-cirrhotic tissues from patients without concomitant HCC to HCV-cirrhotic tissues from patients with HCC, a two-sample t-test was used. The resulting Pvalues were used in estimating false discovery rates (FDR) using the Q-value method (Storey and Tibshirani 2003) ; CpG sites with an FDR \ 0.10 were considered significant.
For the MethyLight reactions, calculations of the methylation rate were calculated as:
where Ct CG (FAM) represents the threshold cycle of the CG reporter (FAM channel), and Ct TG (VIC) represents the threshold cycle of the TG reporter (VIC channel). Samples were evaluated in duplicate and the Ct mean values were used for the final calculation. Pearson's correlation coefficient (q) was calculated to examine the relation between Illumina and MethyLight results and genes with a P-value \0.05 were considered significant.
Results
CpG sites differentially methylated between HCV-cirrhotic tissues from patients with and without HCC We first investigated whether cirrhotic tissues from HCVinfected patients with and without HCC differed with respect to methylation. Statistically, 21 CpG sites were significantly differentially methylated when comparing the non-tumorous HCV-cirrhotic tissues from patients with HCV-HCC to the cirrhotic tissues from patients with HCVcirrhosis without HCC. For each CpG site identified, its distance from the transcription start site (TSS) and whether a CpG island is present in the gene promoter region are provided. It has been demonstrated that transcription binding sites are largely within nucleosome-free regions (NFR) (Li et al. 2007 ). Although for this platform CpG site positioning relative to nucleosomes is not known, one could infer that NFR are predominantly 200 bp upstream of the TSS (Gao et al. 2008; Yuan et al. 2005) . For these 21 CpG sites, the median distance from the TSS was -135. Genes with significant differential CpG site methylation between HCV-cirrhosis with and without concomitant HCC with an absolute difference between proportion methylated of at least 0.17 were ESR1, GSTM2, and MME ( Table 2) . The difference threshold of 0.17 was based on a previous publication in which a maximum standard deviation of 0.06 was observed among technical replicates for 18 gender-specific CpG sites in a mixture study of male and female genomic DNA (Bibikova et al. 2006b ). A representative boxplot of percent methylated for ESR1 demonstrates the increasing methylation pattern in cirrhosis with concomitant HCC compared to cirrhosis without concomintant HCC (Fig. 1) . The ESR1 gene has been associated with a variety of cancers and apart from its role in the estrogen receptor signaling pathway transcription, it has been found to play a role in the regulation of transcription. The GSTM2 gene encodes a glutathione S-transferase that is involved in electrophilic compound Genes are sorted by the difference in proportion methylated between HCV-cirrhotic liver tissues with and without concomitant HCC detoxification. MME is implicated in cancer, particularly leukemia, and its biological functions include proteolysis and cell-cell signaling. The 21 significant genes were subsequently used in performing pathway analyses using the Ingenuity Pathways Analysis software (Ingenuity Ò Systems, Release Number 7.1, www.ingenuity.com). The associated molecular and cellular functions were cellular development (ALK, BMP4, BMP6, ESR1, HOXB13, ITK, MYB, NOTCH4, PGF, SMAD2, TGFB2; P-value range = 0.00000311-0.0132) and cellular growth and proliferation (includes the previous list and additionally, FRK and TMEFF2; P-value range = 0.00000702-0.0132). The top three canonical pathways were factors promoting carcinogenesis in vertebrates (P = 0.00000835), Transforming growth factor beta (TGF-b) signaling (P = 0.000293), and hepatic fibrosis/ hepatic stellate cell activation (P = 0.00111). The TGF-b signaling pathway is involved in a number of cellular processes including cellular growth, differentiation, and apoptosis. Hepatic stellate cell activation leads to the development of hepatic fibrosis, which in patients included in this study, is likely triggered by the inflammatory response due to HCV infection. Severe fibrosis leads to cirrhosis of the liver, which has been described as a premalignant or a preneoplastic condition (McCaughan et al. 2002) .
CpG sites differentially methylated comparing paired HCV-HCC and adjacent HCV-cirrhotic non-tumorous liver tissues
When statistically comparing paired HCV-HCC and adjacent HCV-cirrhotic non-tumorous liver tissue samples, 56 CpG sites (corresponding to 49 unique genes) were identified as differentially methylated. For these 56 CpG sites, the median distance from the TSS was -190. Among these, eight CpG sites exhibited an absolute difference in proportion methylated [ 0.17 (Table 2 ). This included one CpG site that was hypermethylated in HCC tissues compared to the corresponding non-tumorous cirrhotic tissues (APC). The remaining seven (NOTCH4, EMR3, HDAC9, DCL1, HLA-DOA, HLA-DPA1, and ERN1) were hypomethylated in HCC (Table 3) .
CpG sites with significant monotonic trend in proportion methylated among normal, HCV-cirrhosis, and HCV-HCC 235 CpG sites had a significant increasing trend in proportion methylated, with a median distance from the TSS of -221 (hypermethylated), while 266 CpG sites had a significant decreasing trend, with a median distance from the TSS of -188 (hypomethylated), as tissue progressed from normal, to cirrhosis, to HCC (FDR \ 5% each comparison, for total FDR \ 10%). For 50 of the 235 significant CpG sites with a significant increasing trend, the difference in proportion methylated between HCV-HCC and normal exceeded the established threshold of 0.17 (Supplemental Table 1 ). Among these 50 some genes are listed more than once because for some genes the assay interrogates more than one CpG site. CpG sites with significant hypermethylation were located in the promoter regions of genes known to be important in carcinogenesis, included genes associated with other cancers such as ACVR1, ALOX12, COL1A1, DDIT3 FLT3, HOXA5, HOXA9, and MMP14 among others. For 94 of the 266 significant CpG sites with a significant decreasing trend, the absolute value of the difference in proportion methylated between HCV-HCC and normal exceeded the established threshold of 0.17 (Supplemental Table 2 ). BMP4, ESR1, GSTP1, HDAC1, PDGFRB, and RASSF1 were among the CpG sites having a significant decreasing trend and reduced or lost expression of these genes has been noted in other cancers. Based on the Ingenuity Pathways analysis, the top canonical pathway for the CpG sites exhibiting a significant increasing trend was Hepatic Fibrosis/Hepatic Stellate Activation (P = 6.17E-08).
Correlation between Illumina GoldenGate Methylation BeadArray Cancer Panel I and MethyLight
Although the Illumina assay has been rigorously tested (Bibikova et al. 2006a, b) , we examined the concordance of our high-throughput Illumina results using a more sensitive assay, MethyLight for CpGs associated with some selected genes. We found that the proportion methylated obtained from the Illumina methylation assay was significantly correlated with the MethyLight results for APC1, ERBB2, GSTP1, and PITX2 (q = 0.90, P \ 0.0001; q = 0.71, P = 0.001; q = 0.58, P = 0.02; and q = 0.52, P = 0.03, respectively).
Comparison with previous findings
In a recent study that used methylated CpG island amplification microarrays (MCAM), researchers examined 6,458 CpG islands and identified 719 hypermethylated CpG islands (Gao et al. 2008) . However, in this study only 10 HCC patients samples were examined using MCAM and significant CpG islands were determined by a fold-change threshold rather than statistical significance. Nevertheless, when merging these 719 CpG islands by gene symbol to CpG sites identified as statistically significant in the previous analyses, we identified that 43 CpG sites for 32 unique genes were in common between the two studies (Table 4) .
Discussion
Using a high-throughput platform, in this study we identified several CpG sites that were differentially methylated among liver tissues representing the progression from normal, to HCV-cirrrhosis, to HCV-HCC. From our analyses, we found the reproducibility of the Illumina GoldenGate Methylation assay to be very high even for samples that independently underwent bisulfite conversion. We also used MethyLight reactions for validating selected genes identified from the analyses using the Illumina GoldenGate Methylation assay. The MethyLight assay is reproducible and sensitive and its correlation with the Illumina GoldenGate Methylation assay demonstrates we can reliably detect methylation in DNA samples using this highthroughput technology. Our study design was restricted to subjects having the same underlying cirrhosis etiology, as it has been noted that patients with HBV-HCC likely have different malignant transforming mechanisms compared to patients with HCV-HCC (Iizuka et al. 2004; Moinzadeh et al. 2005; Poon et al. 2006) . In fact, the difference between HCV and HBV etiologies was emphasized in two recent methylation studies. In the first, researchers examined methylation of 19 epigenetic markers in 77 paired HCC and matching noncancerous liver tissue along with 22 normal liver tissues (Nishida et al. 2008) . The authors found that 7/19 epigenetic markers (COX2, MINT1, CACNA1G, RASSF2, MINT2, Reprimo, and DCC) were hypermethylated in HCV? tissues in comparison to both HBV? and normal liver tissues. The authors concluded that HCV infection may accelerate the methylation process. In the second, investigators examined 24 different gene promoter regions using MSP in conjunction with DNA sequencing in 28 HBV/HCC tissues and corresponding non-tumorous tissues (Yu et al. 2003) and found that 15 of the 24 were more frequently methylated among HCC versus HCV tissues. This suggests that monitoring important epigenetic markers may be of clinical utility but that different markers would be needed for HCV and HBV. We believe our study design, which, similar to previously published gene expression and microarray studies (Llovet et al. 2006; Wurmbach et al. 2007) , is restricted to patients with a common etiology of HCV infection, is better able to identify molecular events involved in the disease process. Developing an appropriate study design is of vital importance when identifying molecular events in carcinogenesis.
A limitation to our study was the small sample size available for each of tissue type (normal (N = 20), cirrhosis without HCC (N = 16), cirrhosis with concomitant HCC (N = 20), and HCC (N = 20)). However, we were able to corroborate some previous findings. For example, we identified the APC gene to be hypermethylated in HCC tissues compared to adjacent non-tumorous cirrhotic tissues. Other investigators previously found that the APC promoter was hypermethylated in 81.8% of non-cancerous liver tissue samples (Csepregi et al. 2008) . In that study all HCC studied samples and ten patients with liver metastasis (52.6%) exhibited APC promoter methylation. The degree of methylation was significantly higher in samples from HCC compared to the non-cancerous liver tissue samples (63.1 vs. 24.98%; P = 0.001). Moreover, the level of APC protein expression was significantly reduced in HCC samples compared to that of the corresponding non-tumor liver tissue (P \ 0.05). These results suggest that promoter methylation of the APC gene is important in hepatocarcinogenesis, and its hypermethylation results in reduced protein expression in HCC. Interestingly, the APC gene encodes a tumor suppressor protein that has been extensively studied in colon cancer. Though HCC surveillance has been demonstrated to lead to early HCC detection which in turn reduces the percent Table 4 CpG sites identified as statistically significant when comparing paired HCV-HCC and adjacent HCV-cirrhotic non-tumorous tissues (HCC vs adjacent), the independent HCV-cirrhotic tissues from patients without concomitant HCC to HCV-cirrhotic tissues from patients with HCC (Cirrhosis w/wo HCC), with a significant monotonic increasing trend (increasing trend), or with a significant monotonic decreasing trend (decreasing trend), that were also identified as significant in the Gao MCAM study of untreated patients with disease (Trevisani et al. 2007 ), due to the poor sensitivities and specificities of currently used biomarkers, namely AFP and PIVKA-II (Beale et al. 2008 , Ishii et al. 2000 , Sherman 2007 , additional markers that are more sensitive and specific for early HCC detection are needed. We conclude that larger highthroughput DNA methylation studies may reveal important methylation events, such as APC, that may serve as novel biomarkers for HCC screening.
